Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Advances in Minimally Invasive Screening for Lung Cancer
Julie A. Barta, MD, ATSF
Peter J. Mazzone, MD, MPH, FCCP
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Thomas F. Patterson, MD, FACP, FIDSA
George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
Peter G. Pappas, MD, FACP
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.